-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The relationship between familial plasma cell disease (PCD) and monoclonal antibody disease (MGUS), multiple myeloma (MM), and systemic light chain (AL) amyloidosis has not been well described
The relationship between familial plasma cell disease (PCD) and monoclonal antibody disease (MGUS), multiple myeloma (MM), and systemic light chain (AL) amyloidosis has not been well described
Therefore, a foreign research team retrospectively reviewed the results of 25,423 patients (16,744 MGUS, 6194 MM, 2955 AL amyloidosis)
Therefore, a foreign research team retrospectively reviewed the results of 25,423 patients (16,744 MGUS, 6194 MM, 2955 AL amyloidosis)
Familial association of a proband who reports a family history of PCD
The overall survival of patients with a family history of PCD and those without a family history of PCD
The overall survival of patients with a family history of PCD and those without a family history of PCD The overall survival of patients with a family history of PCD and those without a family history of PCD ExpectOverall, 2.
Overall, 2.
The cumulative incidence of MGUS progression to MM, a lymphoproliferative disease, or systemic AL amyloidosis, and death as a competitive risk MGUS progression to MM, a lymphoproliferative disease, or the accumulation of systemic AL amyloidosis Incidence rate, using death as a competitive risk
Although studies have shown that family history of PCD may increase the risk of disease progression, there is currently no data showing that MGUS screening can improve health outcomes
Although studies have shown that family history of PCD may increase the risk of disease progression, there is currently no data showing that MGUS screening can improve health outcomes
Original source:
Original source:Visram, A.
Visram, A.
Leave a message here